Researchers have created a new drug delivery system that could improve the effectiveness of an emerging concept in cancer treatment – to dramatically slow and control tumors on a long-term, sustained basis, not necessarily aiming for their complete elimination.
The approach, called a “metronomic dosage regimen,” uses significantly lower doses of chemotherapeutic drugs but at more frequent time intervals. This would have multiple goals of killing cancer cells, creating a hostile biological environment for their growth, reducing toxicity from the drug regimen and avoiding the development of resistance to the cancer drugs being used.
A system just published in Chemistry of Materials by a group of researchers from Oregon and the United Kingdom offers an even more effective way to deliver such drugs and may be able to greatly improve this approach, scientists say. Further testing is needed in both animals and humans for safety and efficacy.
“This new system takes some existing cancer therapy drugs for ovarian cancer, delivers both of them at the same time and allows them to work synergistically,” said Adam Alani, an associate professor in the Oregon State University/Oregon Health & Science University College of Pharmacy, and lead author on the new study.
“Imagine if we could manage cancer on a long-term basis as a chronic condition, like we now do high blood pressure or diabetes. This could be a huge leap forward.”
This approach is still in trial stages, Alani said, but shows promise. In some prior work with related systems in animal tests, OSU and collaborating researchers have been able to completely eradicate tumors.
Total remission, Alani said, may be possible with metronomic dosage, but the initial goal is not only to kill cancer cells but to create an environment in which it’s very difficult for them to grow, largely by cutting off the large blood supply these types of cells often need.
Most conventional cancer chemotherapy is based on the use of “maximum tolerable doses” of a drug, in an attempt to completely eliminate cancer or tumors. In some cases such as ovarian cancer, however, drug-free intervals are needed to allow patient recovery from side effects, during which tumors can sometimes begin to grow again or develop resistance to the drugs being used.
The types of cancers this approach may best lend itself to are those that are quite complex and difficult to treat with conventional regimens based on “maximum tolerable dose.” This includes ovarian, sarcoma, breast, prostate, and lung cancers.
One example of the new metronomic regimen, in this instance, is use of two drugs already common in ovarian cancer treatment – paclitaxel and rapamycin – but at levels a tenth to a third of the maximum tolerable dose. One drug attacks cancer cells; the other inhibits cancer cell formation and the growth of blood vessels at tumor sites.
The new system developed in this research takes the process a step further. It attaches these drugs to polymer nanoparticles that migrate specifically into cancer cells and are designed to release the drugs at a particular level of acidity that is common to those cells. The low doses, careful targeting of the drugs and their ability to work in synergy at the same time appeared to greatly increase their effectiveness, while almost completely eliminating toxicity.
“Our goal is to significantly reduce tumors, slow or stop their regrowth, and allow a person’s body and immune system time to recover its health and natural abilities to fight cancer,” Alani said. “I’m very optimistic this is possible, and that it could provide an entirely new approach to cancer treatment.”
The Latest on: Metronomic dosage regimen
via Google News
The Latest on: Metronomic dosage regimen
- Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma on May 2, 2018 at 5:00 pm
Conclusion Both dose-dense and metronomic temozolomide regimens were well tolerated with modest toxicity. The dose-dense regimen appears promising, with 1-year survival of 80%. Despite recent advances ... […]
- When Cancer Can't Be Cured, Low-Dose Chemo Aims To Keep It In Check on May 18, 2017 at 5:00 pm
Those are at night." Most of the time, Nick is on this drug regimen, called "low-dose chemo." It's also known as "metronomic therapy" because it's relatively regular, like a metronome. And "adaptive t... […]
- Study shows low-dose chemotherapy regimens could prevent tumor recurrence in some cancers on November 22, 2016 at 4:00 pm
Frequent, low-dose chemotherapy regimens avoid this effect and may therefore be more effective at treating certain types of breast and pancreatic cancer, according to the murine study "Metronomic chem... […]
- The field of cancer is moving towards precision medicine: Dr. Nicolas Andre on September 27, 2016 at 9:17 pm
People are getting used to the ideal of using metronomic chemotherapy and drug repositioning to treat ... How do you see the future of cancer treatment? The field of cancer is moving towards precision ... […]
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer on September 21, 2016 at 5:00 pm
5 Given these considerations, we designed a phase II trial to explore the activity and tolerability of a regimen combining metronomic cyclophosphamide ... To achieve a 50% dose reduction, cyclophospha... […]
- Drug delivery system created to control cancer as chronic condition on August 27, 2016 at 11:30 am
... and the United Kingdom has created a new cancer drug delivery system that builds on a new approach known as "metronomic dosage regimen," which uses significantly lower doses of chemotherapeutic dr... […]
- Maintenance Regimen Fails to Improve DFS in HR-Negative Early Breast Cancer on June 20, 2016 at 2:02 pm
“Preclinical and clinical studies support the notion that less-toxic, low-dose continuous chemotherapy, also called metronomic ... of CM maintenance treatment should not be recommended for women with ... […]
- Tata Memorial docs test low-dose chemo on May 7, 2016 at 10:55 pm
Doctors at Tata Memorial Hospital, Parel, are testing a low-cost, low-dose ... Hospital's metronomic therapy for ovarian cancer recurrence among 26 patients. “We found no difference in survival betwee... […]
- Clinical studies on metronomic therapy needed to offer affordable cancer treatment in LMICs: Experts on May 5, 2016 at 1:00 am
and drug re-positioning might provide a way to overcome major constraints associated with cancer treatment in developing countries. Therefore, there is a need to encourage clinical studies on metronom... […]
- Precision Cancer Treatment: Envita's Published Study on Metronomic Dosing a Game Changer on June 16, 2015 at 10:16 am
the potential to minimize multi drug resistance mutations, and the potential to safely use more than one chemotherapy regimen of treatment.” Furthermore, “Metronomic dosing combined with a patient’s m... […]
via Bing News